Acelyrin (SLRN) Scheduled to Post Earnings on Wednesday

Acelyrin (NASDAQ:SLRN) will announce its earnings results after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

Acelyrin (NASDAQ:SLRN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.08). During the same period in the prior year, the firm posted ($0.56) earnings per share. On average, analysts expect Acelyrin to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acelyrin Stock Performance

Acelyrin stock opened at $6.00 on Thursday. Acelyrin has a 52 week low of $3.36 and a 52 week high of $9.64. The stock has a market cap of $598.86 million, a P/E ratio of -2.11 and a beta of 1.98. The stock has a 50 day moving average of $5.26 and a 200-day moving average of $4.96.

Analysts Set New Price Targets

SLRN has been the subject of several research analyst reports. Wells Fargo & Company boosted their target price on shares of Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 16th. HC Wainwright downgraded shares of Acelyrin from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $18.00 to $6.00 in a research report on Wednesday, August 14th. Piper Sandler reduced their price target on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. Finally, Morgan Stanley decreased their price objective on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating for the company in a report on Monday, August 19th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.17.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.